Alnylam Pharma (ALNY) Tops Q2 EPS by 24c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $227.12 +1.42%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of $1.84, $0.24 better than the analyst estimate of $1.60. Revenue for the quarter came in at $1.29 billion versus the consensus estimate of $1.32 billion.
GUIDANCE:
Alnylam Pharma sees FY2026 revenue of $4.2-4.5 billion, versus the consensus of $5.61 billion.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- zSpace, Inc. (ZSPC) Reports Q2 results
- Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
